ERBB2 and breast carcinoma: Trastuzumab has provided a promising therapeutic advantage in not only breast cancer but in other tumor types; moreover, combination therapy with trastuzumab and chemotherapeutics is generally more effective than single agents in HER2 positive breast and gastric cancer.